Prostate cancer screening is no longer as simple as getting a PSA test and deciding what to do based on one number. PSA remains an important tool, but doctors now have more ways to look at a man’s individual risk before recommending additional testing. Depending on a man’s risk, evaluation may include, evaluation may include repeat PSA testing, risk assessment, blood or urine biomarkers, prostate MRI and, when appropriate, a biopsy.
The goal is not simply to find more prostate cancer. It is to better identify cancers that may need treatment while reducing unnecessary testing and procedures.
What Does Prostate Cancer Screening Mean?
Screening looks for prostate cancer before symptoms develop. It is different from evaluating urinary symptoms or other concerns that may already point to a prostate problem.
There is no single screening schedule that fits every man. Age, family history, genetic risk, overall health, life expectancy, and previous PSA results can all influence when screening should begin and how often it should be repeated.
This is why conversations about prostate cancer screening increasingly focus on overall risk rather than relying on a single PSA cutoff for every patient.
PSA Is Still an Important Tool
PSA, or prostate-specific antigen, is a protein produced by prostate cells and measured through a blood test. PSA can be higher in men with prostate cancer, but it can also rise because of benign prostatic hyperplasia (BPH), prostatitis, infection, and other factors.
Doctors may consider the PSA level, how it changes over time, percent free PSA, and PSA density when assessing risk. Doctors look at the PSA result alongside other factors.
Why One Elevated PSA Does Not Automatically Mean Cancer
An elevated PSA can be concerning, but it does not automatically mean cancer is present. PSA levels can fluctuate, and temporary increases may occur with inflammation, infection, an enlarged prostate, recent prostate procedures, recent ejaculation, and other factors.
For that reason, a doctor may repeat a newly elevated PSA before moving to additional testing. A repeat test can show whether the elevation persists or was temporary.
What Happens After an Abnormal PSA?
If PSA remains elevated, the next step depends on the man’s overall risk. A doctor may recommend additional blood or urine testing, such as the Prostate Health Index (PHI) or 4Kscore, to provide more information about the likelihood of clinically significant prostate cancer. These tests are risk-assessment tools, not definitive cancer tests.
A prostate MRI may also be recommended. MRI can identify areas that look suspicious and may help determine whether a biopsy is needed or help guide biopsy sampling. However, a negative MRI does not completely rule out clinically significant prostate cancer, so results must be considered alongside other risk factors.
A biopsy is used to determine whether cancer is present in prostate tissue.
How Doctors Assess Prostate Cancer Risk
Today’s approach to prostate cancer screening considers a man’s individual risk.
Doctors may consider age, family history, genetic risk, PSA level and trend, prostate size, PSA density, previous biopsy results, MRI findings, and biomarker results. Together, these factors can help determine whether additional testing is warranted.
The process also involves weighing the benefits of finding clinically significant cancer against the potential downsides of false-positive results, unnecessary biopsies, and finding slow-growing cancers that may never cause harm.
Screening Should Be a Conversation
There is no single test or PSA number that determines prostate cancer risk for every man. Screening decisions should take into account individual risk, overall health, life expectancy, and personal preferences.
If you are considering screening, ask your provider:
- When should I begin prostate cancer screening?
- What is my individual risk?
- What does my PSA result mean for me?
- Should I repeat my PSA before additional testing?
- Would an MRI or biomarker test be appropriate?
- If my PSA remains elevated, what should happen next?
PSA remains an important screening tool, but it is only one part of assessing prostate cancer risk. Knowing your risk and discussing your options with a provider at Urology Alliance can help you make informed decisions about prostate cancer screening.
